We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




New X-Ray Source for Molecular Imaging

By Biotechdaily staff writers
Posted on 07 Jul 2005
Scientists are evaluating what they call the "Ferrari” of synchotron beamline-high technology research facilities for imaging molecules.

At the Argonne National Laboratory (Argonne, IL, USA), several innovative design characteristics that allow for automation, additional research stations, and more refined information will enable scientists to study molecules in greater detail and convert these data into new therapeutic medications, eventually benefiting research and human health. More...
The project is supported by the U.S National Institutes of Health (NIH) in collaboration with Argonne National Laboratory, part of the U.S. Department of Energy (DOE).

Synchrotrons produce powerful x-ray beams that scientists utilize use to image the three-dimensional (3D) shapes of molecules. However, only a small amount of these large-scale facilities exist worldwide. Biochemists, biologists, and other scientists apply for access to approximately 45 experimental stations in the United States. Many want time to use the advanced photon source (APS), a DOE-user facility at Argonne offering the most powerful x-ray beams in the Western Hemisphere.

The additional experimental stations at APS can accommodate many robotic and automated tools. This ability could enable scientists to conduct their studies from their home laboratories. The beamlines are the first to also utilize the innovative APS technology that splits one x-ray beam into two and then adjusts each one so it is exactly as strong as the original. "The ability to do two experiments simultaneously from the same light source is a big bonus,” explained Dr. Smith. "It doubles the value of real estate at the synchrotron.”

But where the new beamlines really demonstrate their strength is in their capacity to generate very fine x-ray beams. This characteristic enables scientists to retrieve data on molecules that have been difficult to work with in the past. The new facilities have already produced exciting results. One research group has succeeded in producing a detailed structure of the bacteria-infecting HK97 virus--a significant achievement given that most viruses are complicated and difficult to image at high resolutions. Knowing the structures of viruses and proteins and how they bind to other molecules will help investigators develop drugs that block those interactions.

Structural biologists will have general access to one of the beamlines later in 2005. The team expects all three to be fully operational by summer of 2007.




Related Links:
Argonne National Laboratory

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rheumatoid Factors (RF) Test
Rheumatoid Factors (RF)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.